Clomifene 100 mg (Clomiphene)

Product Overview

Clomifene 100 mg, marketed under the brand name Clomiphene, is a pharmaceutical preparation designed to support ovulation induction in women experiencing fertility challenges. Each strip contains ten tablets, each delivering a precise 100 mg dose of the active compound. The product is manufactured by Healing Pharma, an Indian company with a focus on reproductive health medications. Packaging options include 100, 200, or 300 tablets, allowing clinicians to tailor supply according to treatment length. The medication is classified under female infertility and is intended for oral use only. Shipping typically requires six to fifteen days, depending on the destination and customs processing. The tablets are film‑coated to protect the active ingredient from moisture, and each strip is sealed with a child‑resistant cap to ensure safety. Storage should be at room temperature, away from direct sunlight, and the medication must be kept out of reach of children. Clinicians often prescribe Clomifene as part of a comprehensive fertility assessment that may include hormonal profiling and pelvic ultrasound. The product is supplied with a patient information leaflet that outlines administration instructions and safety considerations.

What is Clomifene 100 mg (Clomiphene)

Clomifene citrate, commonly referred to as clomiphene, belongs to a class of selective estrogen receptor modulators (SERMs). It functions by interacting with estrogen receptors in the hypothalamus, leading to an increase in follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) secretion. The resulting hormonal surge promotes the development and release of mature ovarian follicles, thereby enhancing the likelihood of conception. The 100 mg strength represents a standard tablet strength used in many fertility protocols. For detailed pharmacological data, reputable sources such as the National Institutes of Health provide comprehensive reviews. National Institutes of Health. Its pharmacological profile has been studied in numerous clinical trials, and the drug is listed on the World Health Organization’s Model List of Essential Medicines for reproductive health. World Health Organization

Uses and Benefits

The primary indication for clomiphene is the treatment of anovulation or oligo‑ovulation in women who are attempting to become pregnant. Clinical experience shows that the drug can improve ovulation rates by up to 80 % in appropriate candidates, and pregnancy rates of 30 % to 40 % over six treatment cycles when combined with timed intercourse. Benefits include a non‑invasive oral route, relatively low cost compared with assisted reproductive technologies, and the ability to stimulate multiple follicles in a single cycle, which may increase the chance of conception. Additionally, the medication is often prescribed for polycystic ovary syndrome (PCOS) when other first‑line therapies have not produced satisfactory ovulation. In addition, the medication can be used in conjunction with intrauterine insemination (IUI) protocols to improve implantation chances, and some practitioners employ it as a bridging therapy before considering more invasive assisted reproductive techniques such as IVF.

How It Works

Clomifene acts as a partial agonist in some tissues and an antagonist in others, modulating the body’s natural estrogen feedback loop. By blocking estrogen receptors in the hypothalamus, the pituitary gland perceives lower estrogen levels and responds by secreting increased amounts of FSH and LH. These gonadotropins travel through the bloodstream to the ovaries, encouraging the growth of multiple ovarian follicles. As the follicles mature, they produce estrogen, which eventually leads to a surge in LH that triggers ovulation. This mechanism is why clomiphene is sometimes called an “ovulation inducer.” For a deeper scientific explanation, the U.S. Food and Drug Administration labeling provides detailed pharmacodynamic information. The selective estrogen receptor modulation also explains why some patients experience visual disturbances, as estrogen receptors in the ocular tissue can be affected, leading to transient changes in visual acuity that usually resolve after discontinuation.

Dosage Guidelines

Clomifene is typically administered in a cyclic regimen: one tablet daily for five consecutive days, starting on the fifth day of the menstrual cycle. The standard dose is 100 mg per day, but physicians may adjust the strength based on patient response and tolerability. In some protocols, a lower initial dose of 50 mg is used, with escalation only if ovulation does not occur. It is essential that patients follow the prescribing clinician’s instructions precisely, as misuse can lead to suboptimal ovulation or increased risk of multiple pregnancies. If ovulation occurs but pregnancy does not, the physician may recommend continuing cycles for up to six attempts before considering alternative interventions, and dose escalation is typically limited to a maximum of 200 mg per day in specific cases under close supervision. Patients should never exceed the recommended duration without medical supervision, and any missed dose should be discussed with a healthcare professional before restarting. Detailed dosing algorithms can be found in standard obstetrics textbooks and online resources such as MedlinePlus.

Side Effects

Clomifene can cause adverse reactions, although many are mild and self‑limiting. Common side effects include hot flashes, abdominal discomfort, breast tenderness, and occasional visual disturbances such as blurred vision. Less frequent but more serious events may involve ovarian hyperstimulation syndrome, characterized by rapid weight gain, shortness of breath, and severe pelvic pain, as well as the possibility of multiple gestations. Mood changes, including irritability or depressive symptoms, have also been reported. Rarely, patients may experience ovarian torsion or an increased risk of thromboembolic events, particularly in those with underlying clotting disorders, which necessitates immediate medical evaluation. Patients are advised to monitor their response and report any concerning symptoms to their physician promptly. For a comprehensive list of side effects, the Drugs.com entry provides an accessible overview.

Warnings and Precautions

Clomifene is contraindicated in individuals with known hypersensitivity to the drug, liver disease, ovarian cysts unrelated to polycystic ovary syndrome, and certain cancers such as estrogen‑dependent tumors. It should not be used during pregnancy or while breastfeeding, as the medication can cross the placenta and affect fetal development. Women with a history of thromboembolic disorders or stroke should discuss the risks with their healthcare provider before initiating therapy. Routine laboratory monitoring, including estradiol levels and ultrasound examinations, is recommended to assess ovarian response and to mitigate the chance of overstimulation. Additionally, patients should be aware that the drug may increase the likelihood of multiple births, which carry higher maternal and neonatal risks. Patients should also be counseled to avoid simultaneous use of hormonal contraceptives that contain estrogen, as this can counteract the drug’s mechanism, and to inform any surgical scheduled procedures about the medication to ensure proper peri‑operative management. For official safety communications, the FDA drug safety information page is a reliable reference.

Frequently Asked Questions

Question 1: How long does it take to see ovulation after starting clomiphene?
Answer: Ovulation typically occurs about six to ten days after the last tablet, but timing can vary among individuals. A follow‑up ultrasound or ovulation predictor kit can help confirm the event.

Question 2: Can clomiphene be used by women who have already conceived?
Answer: No. The medication is intended solely for stimulating ovulation in women who are not yet pregnant. Continuing use after a confirmed pregnancy is not recommended.

Question 3: Is it safe to combine clomiphene with other fertility drugs?
Answer: Combination therapy is possible but must be supervised by a qualified clinician. Using clomiphene alongside gonadotropins or other ovulation agents can increase the risk of ovarian hyperstimulation and multiple pregnancies.

Question 4: What should I do if I miss a dose during the five‑day course?
Answer: If a dose is missed, the patient should contact their prescribing physician before taking an extra tablet. Skipping doses or doubling up can disrupt the hormonal balance and affect ovulation.

Question 5: Are there lifestyle changes that improve the effectiveness of clomiphene?
Answer: Maintaining a healthy body weight, balanced nutrition, regular exercise, and avoidance of smoking or excessive alcohol can optimize hormonal function and improve ovulation rates.

Related Products

• Tretinoin 0.025% Cream (TRETINOIN)
• Azelax Cream (Azelaic Acid)
• Tretinoin 0.1% Cream (Tretinoin)
• Tretinoin Cream
• Tretinoin 0.05% Cream (TRETINOIN)
• Accufine 40 mg (Isotretinoin)
• Accufine 30 mg (Isotretinoin)
• Tretiheal 0.025% Cream (Tretinoin)
• Tretiheal 0.05% Cream (Tretinoin)
• Tretiheal 0.1% Cream (Tretinoin)
• Accufine 5 mg (Isotretinoin)
• Accufine 20 mg Softgel Capsule (Isotretinoin)